ClinicalTrials.gg
CompletedNCT02172040Updated Oct 10, 2018Results posted

Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

A Phase 3 interventional study of Over-encapsulated 10 mg amlodipine besylate tablet and Matched placebo capsule for over-encapsulated celecoxib capsule in Hypertension, sponsored by Kitov Pharmaceuticals, Ltd.. Completed at 10 sites in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Kitov Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
101st of 186
152 · median 180
Started
2014
with 11 others
Phase 3
69 of 187
2 open now
Registered
122nd of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 101st largest by enrollment of the 186 interventional ones that give a count, is one of 12 that started in 2014, is one of 69 in phase 3, and was the 122nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy.

This study was conducted to support a future marketing application for KIT-302. Kitov Pharma Ltd. (Kitov) is developing KIT-302, an oral fixed combination drug product (FCDP) consisting of the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, as a "convenience reformulation" FCDP to facilitate and improve patient compliance with the once a day (qd) administration of its individual components, amlodipine and celecoxib.

The formulation of KIT-302 consists of amlodipine besylate and celecoxib co-formulated in a single immediate release tablet. However, for this study, two separate capsules were utilized: one containing a commercial celecoxib capsule (Celebrex®) or matched placebo capsule and one containing a commercial amlodipine besylate tablet (Norvasc®) or matched placebo tablet.

The study hypothesis was that treatment with the amlodipine besylate containing capsule plus the celecoxib containing capsule would reduce blood pressure (BP) in subjects with hypertension with an efficacy that is not substantially inferior to the effect of amlodipine besylate alone (i.e., the amlodipine containing capsule plus the matched placebo for the celecoxib capsule).

The United States (US) Food and Drug Administration (FDA) recently approved KIT-302, under the brand name Consensi® (amlodipine and celecoxib) tablets [New Drug Application (NDA) 210045] for the following indication: "patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions."

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High blood pressure
  • Systolic blood pressure
  • Diastolic blood pressure
  • Antihypertensive
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult 40 to 75 years of age
  2. Newly diagnosed hypertension that requires chronic pharmacological therapy. Specifically, the subject must meet both of the following criteria:

    1. Resting systolic BP ≥140 mmHg and ≤179 mmHg (where resting is defined as supine for at least 10 minutes with minimal interaction) at Initial Screening Visit
    2. SBPday >135 mmHg at Baseline Visit (Day 0)
  3. of 18.5 to 34.9 kg/m2
  4. Healthy (other than hypertension) as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead (ECG), and clinical laboratory tests
  5. A negative pregnancy test at Screening
  6. Both males and women of child bearing potential agree to use adequate methods while on study (from Screening through final study visit)
  7. Able to comprehend and sign an form

Exclusion criteria

Exclusion Criteria:

  1. Resting systolic BP >179 mmHg or a resting diastolic BP >110 mmHg at Screening (where resting is defined as supine for at least 10 minutes with minimal interaction) or SBP24h >169 mmHg or DBP24h >110 mmHg at randomization
  2. SBPday ≤135 mmHg at baseline (Day 0)
  3. Weight \<55 kg
  4. Fragile health
  5. Evidence of findings on screening evaluations (clinical, laboratory, and ) which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of safety data
  6. Current or recent history (within 4 weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
  7. Current clinically significant viral infection
  8. History of , with the exception of cured basal cell or squamous cell carcinoma of the skin
  9. Major surgery within 4 weeks prior to Screening
  10. Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn's disease or chronic pancreatitis)
  11. Active peptic ulceration or history of gastrointestinal bleeding
  12. History of myocardial infarction, congestive heart failure, or stroke
  13. Any current cardiovascular disease
  14. History of psychotic disorder
  15. History of alcoholism or drug addiction or current alcohol or drug use that, in the opinion of the Investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations
  16. History of any illicit drug use within one year prior to Screening
  17. Positive drug screen at Screening. A positive drug screen for opiates only (with all other drug tests negative) will not be a basis for exclusion if the subject took over-the-counter narcotics as indicated on the product label within 24 hours prior to the drug screen
  18. Current treatment or treatment within 30 days prior to first dose of study drugs with another drug or current enrollment in another clinical trial
  19. Current treatment or treatment within 30 days prior to first dose of study drugs with an NSAID or systemic
  20. Known history of , , or
  21. Known to amlodipine or celecoxib
  22. Known hypersensitivity to the inactive ingredients in the over-encapsulated study drugs
  23. Asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors
  24. Subjects who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
  25. Pregnant or lactating
  26. Unable to correctly use ambulatory blood pressure monitor after instruction on its use
  27. Subjects with Class B or C cirrhosis;
  28. Subjects currently taking a calcium channel blocker for any reason including angina. Subjects will not be withdrawn from these drugs to be enrolled in the trial
  29. \<50 ml/min as estimated by the Cockroft-Gault equation
  30. Known cytochrome P450 2C9 poor metabolizer
  31. Subjects with allergy or hypersensitivity to sulfonamides
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Amlodipine+Celecoxib

    Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks

    Drug: Over-encapsulated 10 mg amlodipine besylate tablet · Drug: Over-encapsulated 200 mg celecoxib capsule

  • Active comparator
    Amlodipine+Placebo

    Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

    Drug: Over-encapsulated 10 mg amlodipine besylate tablet · Drug: Matched placebo capsule for over-encapsulated celecoxib capsule

  • Placebo comparator
    Placebo+Celecoxib

    Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks

    Drug: Over-encapsulated 200 mg celecoxib capsule · Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet

  • Sham comparator
    Placebo+Placebo

    Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

    Drug: Matched placebo capsule for over-encapsulated celecoxib capsule · Drug: Matched placebo capsule for over-encapsulated amlodipine besylate tablet

Interventions

  • Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks

    Also known as: Norvasc

  • DrugMatched placebo capsule for over-encapsulated celecoxib capsule

    Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

    Also known as: Placebo

  • Over-encapsulated 200 mg celecoxib capsule once a day for two weeks

    Also known as: Celebrex

  • DrugMatched placebo capsule for over-encapsulated amlodipine besylate tablet

    Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint

    Time frame: Baseline and 2 weeks

  2. Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)

    Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\].

    Time frame: 1 month

Secondary outcomes

  1. Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)

    Time frame: Baseline and 2 weeks

  2. Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)

    Time frame: Baseline and 2 weeks

  3. Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)

    Time frame: Baseline and 2 weeks

  4. Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)

    Time frame: Baseline and 2 weeks

  5. Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)

    Time frame: Baseline and 2 weeks

  6. Mean Non-transformed Amlodipine Plasma Concentration

    Time frame: 24 hours post-dose on Day 14

  7. Mean Non-transformed Celecoxib Plasma Concentration

    Time frame: 24 hours post-dose on Day 14

  8. Mean Log-transformed Amlodipine Plasma Concentration

    Time frame: 24 hours post-dose on Day 14

  9. Mean Log-transformed Celecoxib Plasma Concentration

    Time frame: 24 hours post-dose on Day 14

  10. Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint

    Time frame: Baseline and 2 weeks

07

Results

Posted Oct 3, 2017
Limitations and caveats
No limitations

Participant flow

Participant flow — Overall Study
MilestoneAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Started49453127
Completed49422926
Not completed0321
Withdrew: Adverse event0200
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject0010
Withdrew: Not available for day 13 & 14 visits0010
Withdrew: Family emergency abroad0001

Outcome measures

PrimaryMean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint-10.6 ± 9.2-8.83 ± 8.13-0.5 ± 8.8-2.11 ± 8.2
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = = 0.001
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.491
PrimaryFrequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)

Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug \[i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug\].

Time frame:
1 month
Reported as:
Count of participants · Participants
Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)
ParticipantsAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)27281410
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo vs Placebo+Celecoxib vs Placebo+Placebo · Chi-squared · p = = 0.166
SecondaryMean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)-10.3 ± 8.9-8.02 ± 7.6-0.5 ± 7.8-1.19 ± 5.87
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = 0.177
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.719
SecondaryMean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)-10.5 ± 10.6-6.35 ± 11.35-1.7 ± 12.3-1.42 ± 9.15
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = = 0.069
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.097
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = = 0.064
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.924
SecondaryMean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)-7.1 ± 5.6-4.8 ± 4.83-0.5 ± 4.60.22 ± 4.28
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = = 0.038
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.562
SecondaryMean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)-7.5 ± 6.4-5.53 ± 5.06-1.5 ± 5.6-0.32 ± 5.39
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = = 0.104
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.002
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.419
SecondaryMean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)-7.0 ± 8.6-3.23 ± 7.790.3 ± 7.10.01 ± 6.23
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = = 0.028
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.051
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = = 0.074
  • Placebo+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = = 0.878
SecondaryMean Non-transformed Amlodipine Plasma Concentration
Time frame:
24 hours post-dose on Day 14
Reported as:
Mean · pg/mL
Mean Non-transformed Amlodipine Plasma Concentration
pg/mLAmlodipine+CelecoxibAmlodipine+Placebo
Mean Non-transformed Amlodipine Plasma Concentration15,800.83 ± 4,161.92923,453 ± 5,746.337
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = <0.001
SecondaryMean Non-transformed Celecoxib Plasma Concentration
Time frame:
24 hours post-dose on Day 14
Reported as:
Mean · ng/mL
Mean Non-transformed Celecoxib Plasma Concentration
ng/mLAmlodipine+CelecoxibPlacebo+Celecoxib
Mean Non-transformed Celecoxib Plasma Concentration139.708 ± 86.504138.667 ± 118.811
Statistical analysis
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.977
SecondaryMean Log-transformed Amlodipine Plasma Concentration
Time frame:
24 hours post-dose on Day 14
Reported as:
Mean · log(pg/mL)
Mean Log-transformed Amlodipine Plasma Concentration
log(pg/mL)Amlodipine+CelecoxibAmlodipine+Placebo
Mean Log-transformed Amlodipine Plasma Concentration9.634 ± 0.26810.025 ± 0.310
Statistical analysis
  • Amlodipine+Celecoxib vs Amlodipine+Placebo · t-test, 1 sided · p = <0.001
SecondaryMean Log-transformed Celecoxib Plasma Concentration
Time frame:
24 hours post-dose on Day 14
Reported as:
Mean · log(ng/mL)
Mean Log-transformed Celecoxib Plasma Concentration
log(ng/mL)Amlodipine+CelecoxibPlacebo+Celecoxib
Mean Log-transformed Celecoxib Plasma Concentration4.785 ± 0.5644.636 ± 0.781
Statistical analysis
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = = 0.527
SecondaryMean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint
Time frame:
Baseline and 2 weeks
Reported as:
Mean · mmHg
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint
mmHgAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint-10.6 ± 9.2-8.83 ± 8.13-0.5 ± 8.8-2.11 ± 8.2
Statistical analysis
  • Amlodipine+Celecoxib vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Celecoxib vs Placebo+Placebo · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Celecoxib · t-test, 1 sided · p = <0.001
  • Amlodipine+Placebo vs Placebo+Placebo · t-test, 1 sided · p = = 0.001

Adverse events

Collected over 1 month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine+Celecoxib0/49 (0%)0/49 (0%)17/49 (34.7%)
Amlodipine+Placebo0/45 (0%)0/45 (0%)17/45 (37.8%)
Placebo+Celecoxib0/31 (0%)0/31 (0%)5/31 (16.1%)
Placebo+Placebo0/27 (0%)0/27 (0%)6/27 (22.2%)
Most frequent other events
Most frequent other events
EventAmlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+Placebo
Oedema peripheralGeneral disorders4/497/450/310/27
HeadacheNervous system disorders4/496/452/312/27
NasopharyngitisInfections and infestations5/490/452/310/27
Joint swellingMusculoskeletal and connective tissue disorders5/493/450/310/27
DiarrhoeaGastrointestinal disorders2/494/450/310/27
GoutMetabolism and nutrition disorders0/490/450/312/27
Orthostatic hypotensionVascular disorders0/492/450/312/27
Upper respiratory tract infectionInfections and infestations0/492/452/311/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Amlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+PlaceboTotal
Mean57.7 ± 8.057.3 ± 9.454.9 ± 8.252.5 ± 9.156.1 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+PlaceboTotal
Female1719101056
Male3226211796
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Amlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+PlaceboTotal
American Indian or Alaska Native00000
Asian30115
Native Hawaiian or Other Pacific Islander00000
Black or African American02103
White46432926144
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Amlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+PlaceboTotal
United Kingdom49453127152
Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday)
Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday)(mmHg)Amlodipine+CelecoxibAmlodipine+PlaceboPlacebo+CelecoxibPlacebo+PlaceboTotal
Mean148.7 ± 7.4147.6 ± 8.7150.8 ± 8.9147.3 ± 8.6148.5 ± 8.4
08

Study locations

10 sites
  • Celerion
    Belfast, Antrim BT9 6AD, United Kingdom
  • The Medicines Evaluation Unit Ltd.
    Manchester, Greater Manchester M23 9QZ, United Kingdom
  • Reading Clinical Research Aspect
    Ledbury, Herefordshire HR8 2AA, United Kingdom
  • Synexus Merseyside Clinical Research Centre
    Liverpool, Merseyside L22 0LG, United Kingdom
  • Oldfield Surgery
    Bath, North East Somerset BA2 3HT, United Kingdom
  • Rowden Surgery
    Chippenham, Wiltshire SN15 2SB, United Kingdom
  • Synexus Midlands Clinical Research Centre
    Birmingham, B15 2SQ, United Kingdom
  • Synexus Scotland Clinical Research Centre
    Glasgow, G20 0SP, United Kingdom
  • Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London
    London, EC1M 6BQ, United Kingdom
  • Reading Clinical Research Aspect
    Reading, RG6 6BZ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Nov 2015, 16 months.

Results were first posted in Oct 2017, 1 year 10 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 16 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
StartActual
Jun 26, 2014
Primary completionActual
Nov 19, 2015
CompletionActual
Nov 19, 2015
Results first posted
Oct 3, 2017
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02172040
Lead sponsor
Kitov Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Jun 26, 2014
Primary completion
Nov 19, 2015
Completion
Nov 19, 2015
Results posted
Oct 3, 2017
Last update
Oct 10, 2018

Study contacts

J. Paul Waymack, MD, ScD
study director · Kitov Pharma Ltd
Brendan Colgan, MD
principal investigator · Celerion
Claire Kightley, MB
principal investigator · Reading Clinical Research Aspect
David Collier, MBBS, PhD, BSc
principal investigator · Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London
Paul Ivan, MBBS
principal investigator · Synexus Merseyside Clinical Research Centre
Veronika Horvathova, MD
principal investigator · Synexus Scotland Clinical Research Centre
Amit Mathew, MS, MBBS
principal investigator · Synexus Midlands Clinical Research Centre
Alexander Thompson, MB, BS, DRCOG
principal investigator · Reading Clinical Research Aspect
Mohamed Okily, MB
principal investigator · Synexus Manchester Clinical Research Centre
Richard Gaunt, MB, ChB, MRCGP, DRCOG
principal investigator · Rowden Surgery
Patrick Eavis, MBBS, DRCOG, DFFP, MRCGP
principal investigator · Oldfield Surgery
Arjun Ravi, MBBS, MRCP
principal investigator · The Medicines Evaluation Unit Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Celecoxib

Start the discussion